US2418499A
(en)
|
1944-06-20 |
1947-04-08 |
Du Pont |
2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
|
GB849541A
(en)
|
1956-02-23 |
1960-09-28 |
Rohm & Haas |
Preparation of unsaturated cyclic urea derivatives
|
DE1273533B
(de)
|
1962-09-08 |
1968-07-25 |
Hoechst Ag |
Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
|
NL128370C
(es)
|
1964-08-28 |
|
|
|
US3523121A
(en)
|
1967-03-09 |
1970-08-04 |
Rohm & Haas |
Certain 2-carbamoyl-3-isothiazolenes
|
US3573308A
(en)
|
1969-04-03 |
1971-03-30 |
Hoffmann La Roche |
3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
|
US3957808A
(en)
|
1969-09-03 |
1976-05-18 |
Rohm And Haas Company |
3-alkoxyisothiazoles
|
US3998815A
(en)
|
1974-06-24 |
1976-12-21 |
Interx Research Corporation |
1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
|
US4727151A
(en)
|
1974-06-24 |
1988-02-23 |
Interx Research Corporation |
Labile quaternary ammonium salts as prodrugs
|
US4204065A
(en)
|
1975-09-22 |
1980-05-20 |
Interx Research Corporation |
Soft quaternary surface active agents and method of using same
|
JPS5331676A
(en)
|
1976-09-06 |
1978-03-25 |
Mitsui Toatsu Chem Inc |
Uracil derivatives and their preparation
|
US4260769A
(en)
|
1977-04-22 |
1981-04-07 |
Interx Research Corporation |
5,5-Diphenylhydantoins
|
JPS54130587A
(en)
|
1978-03-30 |
1979-10-09 |
Otsuka Pharmaceut Co Ltd |
Carbostyryl derivative
|
JPS568318A
(en)
|
1979-06-28 |
1981-01-28 |
Janssen Pharmaceutica Nv |
Non oral long acting composition of haloperidol and bromperidol derivative
|
DE3149010A1
(de)
|
1981-12-10 |
1983-07-07 |
A. Nattermann & Cie GmbH, 5000 Köln |
(+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
|
US4428935A
(en)
|
1982-05-24 |
1984-01-31 |
Pfizer Inc. |
Penicillanic acid dioxide prodrug
|
IT1212743B
(it)
|
1983-05-17 |
1989-11-30 |
Dompe Farmaceutici Spa |
Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
|
JPS602331A
(ja)
|
1983-06-20 |
1985-01-08 |
Yoshino Kogyosho Co Ltd |
飽和ポリエステル樹脂製壜の成形方法
|
US4760057A
(en)
|
1983-06-23 |
1988-07-26 |
Merck & Co., Inc. |
(Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
|
DK302883D0
(da)
|
1983-06-30 |
1983-06-30 |
Hans Bundgaard |
Allopurinol prodrugs
|
DE3544134A1
(de)
|
1984-12-15 |
1986-06-19 |
Mitsubishi Chemical Industries Ltd., Tokio/Tokyo |
Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
|
GB8513754D0
(en)
|
1985-05-31 |
1985-07-03 |
Jones T R |
Anti-cancer quinazoline derivatives
|
DK588486A
(da)
|
1985-12-09 |
1987-06-10 |
Otsuka Pharma Co Ltd |
Anvendelse af en forbindelse til behandling af hypoxi
|
GB8607683D0
(en)
|
1986-03-27 |
1986-04-30 |
Ici Plc |
Anti-tumor agents
|
US4925860A
(en)
|
1987-08-05 |
1990-05-15 |
E. I. Du Pont De Nemours And Company |
Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
|
US5006528A
(en)
|
1988-10-31 |
1991-04-09 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives
|
WO1991000863A1
(en)
|
1989-07-07 |
1991-01-24 |
Pfizer Inc. |
Heteroaryl piperazine antipsychotic agents
|
US5350747A
(en)
|
1989-07-07 |
1994-09-27 |
Pfizer Inc |
Heteroaryl piperazine antipsychotic agents
|
US5229382A
(en)
|
1990-04-25 |
1993-07-20 |
Lilly Industries Limited |
2-methyl-thieno-benzodiazepine
|
JP2800953B2
(ja)
|
1990-07-06 |
1998-09-21 |
住友製薬株式会社 |
新規なイミド誘導体
|
US5206386A
(en)
|
1991-03-20 |
1993-04-27 |
Isp Investments Inc. |
Controlled release N-substituted pyrrolidone esters and process for the use thereof
|
AU645681B2
(en)
|
1991-05-02 |
1994-01-20 |
John Wyeth & Brother Limited |
Piperazine derivatives
|
TW226016B
(es)
|
1991-12-30 |
1994-07-01 |
Sterling Winthrop Inc |
|
US5462934A
(en)
|
1992-03-09 |
1995-10-31 |
Takeda Chemical Industries |
Condensed heterocyclic ketone derivatives and their use
|
AU4534593A
(en)
|
1992-06-12 |
1994-01-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
HUT72307A
(en)
|
1993-03-08 |
1996-04-29 |
Eisai Co Ltd |
Phosphonic acid derivatives
|
TW376319B
(en)
|
1993-04-28 |
1999-12-11 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
|
DE4439493A1
(de)
|
1994-10-25 |
1996-05-02 |
Schering Ag |
Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
|
JP3571795B2
(ja)
|
1995-04-18 |
2004-09-29 |
株式会社日本触媒 |
N−(1−アルキルオキシアルキル)カルバメート類の気相分子内脱アルコール反応用触媒およびn−ビニルカルバメート類の製造方法
|
US7833543B2
(en)
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
EA000976B1
(ru)
|
1996-03-25 |
2000-08-28 |
Эли Лилли Энд Компани |
Композиция для снятия боли и способ снятия боли
|
DE19619819A1
(de)
|
1996-05-16 |
1997-11-20 |
Boehringer Mannheim Gmbh |
Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
|
CZ299790B6
(cs)
|
1996-08-22 |
2008-11-26 |
Skyepharma Canada Inc. |
Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
|
EP0986403B1
(en)
|
1997-06-13 |
2003-11-12 |
Cydex Inc. |
Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components
|
JP4503826B2
(ja)
|
1997-09-30 |
2010-07-14 |
イーライ リリー アンド カンパニー |
2−メチル−チエノ−ベンゾジアゼピン製剤
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
US6180095B1
(en)
|
1997-12-17 |
2001-01-30 |
Enzon, Inc. |
Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
|
WO1999033846A2
(en)
|
1997-12-31 |
1999-07-08 |
The University Of Kansas |
Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
|
NZ509781A
(en)
|
1998-08-26 |
2003-05-30 |
Aventis Pharma Ltd |
Quinoline or indolyl derivativees useful for modulating the inhibition of cell adhesion
|
FR2783519B1
(fr)
|
1998-09-23 |
2003-01-24 |
Sod Conseils Rech Applic |
Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
|
US7374779B2
(en)
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US20060034937A1
(en)
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
CA2311734C
(en)
|
2000-04-12 |
2011-03-08 |
Bristol-Myers Squibb Company |
Flash-melt oral dosage formulation
|
TWI270545B
(en)
|
2000-05-24 |
2007-01-11 |
Sugen Inc |
Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
US6656505B2
(en)
|
2000-07-21 |
2003-12-02 |
Alpharma Uspd Inc. |
Method for forming an aqueous flocculated suspension
|
US20030049320A1
(en)
|
2000-12-18 |
2003-03-13 |
Wockhardt Limited |
Novel in-situ forming controlled release microcarrier delivery system
|
US7053092B2
(en)
|
2001-01-29 |
2006-05-30 |
Otsuka Pharmaceutical Co., Ltd. |
5-HT1a receptor subtype agonist
|
WO2002064578A1
(en)
|
2001-02-14 |
2002-08-22 |
Warner-Lambert Company Llc |
Benzo thiadiazine matrix metalloproteinase inhibitors
|
US20060293217A1
(en)
|
2001-03-19 |
2006-12-28 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained release
|
WO2002074247A2
(en)
|
2001-03-19 |
2002-09-26 |
Praecis Pharmaceuticals Incorporated |
Pharmaceutical formulations for sustained release
|
US6686377B2
(en)
|
2001-04-03 |
2004-02-03 |
Aryx Therapeutics |
Ultrashort-acting opioids for transdermal application
|
MY129350A
(en)
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
AR033485A1
(es)
|
2001-09-25 |
2003-12-26 |
Otsuka Pharma Co Ltd |
Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
|
TW200403223A
(en)
|
2002-02-15 |
2004-03-01 |
Glaxo Group Ltd |
Novel compounds
|
AU2003257145B2
(en)
|
2002-08-02 |
2008-11-13 |
Merck Sharp & Dohme Corp. |
Substituted furo (2,3-b) pyridine derivatives
|
CA2495864C
(en)
|
2002-08-20 |
2011-09-27 |
Bristol-Myers Squibb Company |
Aripiprazole complex formulation and method
|
RS20050195A
(en)
|
2002-09-17 |
2007-08-03 |
Warner Lambert Company Llc., |
Heterocyclic substituted piperazines for the treatment of schizophrenia
|
US7148211B2
(en)
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20050058734A1
(en)
|
2002-12-18 |
2005-03-17 |
Algorx |
Administration of capsaicinoids
|
MXPA05006670A
(es)
|
2002-12-18 |
2005-10-19 |
Algorx Pharmaceuticals Inc |
Administracion de capsaicinoides.
|
DE10303669A1
(de)
|
2003-01-28 |
2004-07-29 |
Hans-Knöll-Institut für Naturstoff-Forschung e.V. |
Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
CN1826331A
(zh)
|
2003-04-03 |
2006-08-30 |
塞马福尔药业公司 |
Pi-3激酶抑制剂前药
|
CN102172402A
(zh)
|
2003-05-23 |
2011-09-07 |
大塚制药株式会社 |
用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
|
MXPA06000942A
(es)
|
2003-07-24 |
2006-03-30 |
Merial Ltd |
Nuevas formulaciones de vacunas.
|
US6987111B2
(en)
|
2003-08-06 |
2006-01-17 |
Alkermes Controlled Therapeutics, Ii |
Aripiprazole, olanzapine and haloperidol pamoate salts
|
US20050032811A1
(en)
*
|
2003-08-06 |
2005-02-10 |
Josiah Brown |
Methods for administering aripiprazole
|
US7160888B2
(en)
|
2003-08-22 |
2007-01-09 |
Warner Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
|
WO2005022155A1
(ja)
|
2003-08-29 |
2005-03-10 |
Kabushiki Kaisha Toshiba |
発色試薬、濃度測定用キット、濃度測定方法及びそれに用いるセンサチップ
|
ES2315721T5
(es)
|
2003-10-23 |
2012-08-24 |
Otsuka Pharmaceutical Co., Ltd. |
Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
|
JP2007517014A
(ja)
|
2003-12-31 |
2007-06-28 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
N−置換ピペリジン及びピペラジン誘導体
|
KR20060110006A
(ko)
|
2004-02-13 |
2006-10-23 |
화이자 프로덕츠 인크. |
비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물
|
US7169803B2
(en)
|
2004-03-15 |
2007-01-30 |
Bristol-Myers Squibb Company |
N-substituted prodrugs of fluorooxindoles
|
US7119214B2
(en)
|
2004-04-13 |
2006-10-10 |
Cephalon France |
Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
|
GB2413795A
(en)
|
2004-05-05 |
2005-11-09 |
Cipla Ltd |
Process for the preparation of rosiglitazone
|
WO2006037090A2
(en)
|
2004-09-28 |
2006-04-06 |
Purdue Research Foundation |
Drug-phosphate conjugates as prodrugs
|
EP2623095A1
(en)
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
WO2006082588A2
(en)
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
WO2006090273A2
(en)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
|
CN101198331B
(zh)
|
2005-06-13 |
2012-05-02 |
大日本住友制药株式会社 |
增溶化制剂
|
WO2007035348A2
(en)
|
2005-09-15 |
2007-03-29 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
EP1777222A1
(en)
|
2005-09-22 |
2007-04-25 |
Galantos Pharma GmbH |
Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
|
CA2627779A1
(en)
|
2005-10-31 |
2007-05-10 |
Pfizer Products Inc. |
Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
|
US20070185069A1
(en)
|
2005-11-14 |
2007-08-09 |
Plum Stacy M |
Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
|
AU2007291235A1
(en)
|
2006-08-31 |
2008-03-06 |
H. Lundbeck A/S |
Bifeprunox doses for treating schizophrenia
|
US20090068290A1
(en)
|
2006-08-31 |
2009-03-12 |
Michel Bourin |
Bifeprunox doses for treating schizophrenia
|
WO2008034041A2
(en)
|
2006-09-15 |
2008-03-20 |
Astrazeneca Ab |
Therapeutic combinations
|
US20090291134A1
(en)
|
2006-11-21 |
2009-11-26 |
Jina Pharmaceuticals, Inc. |
Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
|
AU2007328007A1
(en)
|
2006-12-05 |
2008-06-12 |
Neurogesx, Inc. |
Prodrugs and methods of making and using the same
|
AU2007334343A1
(en)
|
2006-12-15 |
2008-06-26 |
Ordway Research Institute, Inc. |
Treatments of therapy-resistant diseases comprising drug combinations
|
EP1961412A1
(en)
|
2006-12-27 |
2008-08-27 |
LEK Pharmaceuticals D.D. |
Self-microemulsifying drug delivery systems
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
JP2010522198A
(ja)
|
2007-03-19 |
2010-07-01 |
アカドイア プハルマセウチカルス インコーポレーテッド |
5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用
|
KR101562835B1
(ko)
|
2007-04-04 |
2015-10-23 |
머크 샤프 앤드 돔 코포레이션 |
치료제
|
WO2009012096A2
(en)
|
2007-07-18 |
2009-01-22 |
Research Development Foundation |
Improved therapeutic methods and compositions comprising chroman ring compounds
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
CN101795670A
(zh)
*
|
2007-08-27 |
2010-08-04 |
百奥杰诺瑞克斯股份有限公司 |
G-csf的液体制剂
|
WO2009052467A1
(en)
|
2007-10-19 |
2009-04-23 |
Board Of Regents Of The University Of Texas System |
Methods of identifying pi-3-kinase inhibitor resistance
|
CL2008003305A1
(es)
|
2007-11-06 |
2009-06-05 |
M/S Panacea Biotec Ltd |
Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
|
CN105560176A
(zh)
|
2007-12-19 |
2016-05-11 |
詹森药业有限公司 |
与长效注射用帕潘立酮酯相关的给药方案
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
US9161943B2
(en)
|
2007-12-31 |
2015-10-20 |
Industrial Technology Research Institute |
Sustained release composition and manufacturing method thereof
|
WO2009126931A2
(en)
|
2008-04-11 |
2009-10-15 |
Xvasive, Inc. |
Combination therapy for bipolar disorder
|
EP2323622A1
(en)
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
US8017515B2
(en)
|
2008-12-10 |
2011-09-13 |
Stats Chippac, Ltd. |
Semiconductor device and method of forming compliant polymer layer between UBM and conformal dielectric layer/RDL for stress relief
|
EP2389169A1
(en)
|
2009-01-26 |
2011-11-30 |
Egalet A/S |
Controlled release formulations with continuous efficacy
|
US20100286136A1
(en)
|
2009-05-08 |
2010-11-11 |
Simon Jones |
Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
|
US8431576B2
(en)
|
2009-06-25 |
2013-04-30 |
Alkermes Pharma Ireland Limited |
Heterocyclic compounds for the treatment of neurological and psychological disorders
|
JP5732453B2
(ja)
|
2009-06-25 |
2015-06-10 |
アルカーメス ファーマ アイルランド リミテッド |
Nh酸性化合物のプロドラッグ
|
WO2011000546A1
(de)
|
2009-07-01 |
2011-01-06 |
Bayer Materialscience Ag |
Verfahren zur herstellung eines polyurethan-polymers mit sekundären hydroxyl-endgruppen umfassenden polyesterpolyolen
|
NZ599558A
(en)
|
2009-10-30 |
2014-09-26 |
Janssen Pharmaceutica Nv |
Dosing regimen associated with long-acting injectable paliperidone esters
|
US20110166128A1
(en)
|
2010-01-07 |
2011-07-07 |
Alkermes, Inc. |
Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
|
US20110166194A1
(en)
|
2010-01-07 |
2011-07-07 |
Alkermes, Inc. |
Asenapine Prodrugs
|
US9107911B2
(en)
|
2010-01-07 |
2015-08-18 |
Alkermes Pharma Ireland Limited |
Prodrugs of heteraromatic compounds
|
US20110166156A1
(en)
|
2010-01-07 |
2011-07-07 |
Alkermes, Inc. |
Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
|
WO2011084846A1
(en)
|
2010-01-07 |
2011-07-14 |
Alkermes, Inc. |
Quaternary ammonium salt prodrugs
|
WO2011102316A1
(ja)
|
2010-02-16 |
2011-08-25 |
浜松ホトニクス株式会社 |
ガス濃度算出装置及びガス濃度計測モジュール
|
AU2011248194B2
(en)
|
2010-05-04 |
2015-06-04 |
Alkermes Pharma Ireland Limited |
Process for synthesizing oxidized lactam compounds
|
US8592427B2
(en)
|
2010-06-24 |
2013-11-26 |
Alkermes Pharma Ireland Limited |
Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
CN102525915B
(zh)
*
|
2010-12-14 |
2016-09-28 |
江苏豪森药业集团有限公司 |
一种持续释放的注射制剂及其制备方法和用途
|
IL296695A
(en)
|
2011-03-18 |
2022-11-01 |
Alkermes Pharma Ireland Ltd |
Pharmaceutical preparations containing sorbitan esters
|
CA2867123C
(en)
|
2012-03-19 |
2021-02-16 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
|
WO2013142198A1
(en)
*
|
2012-03-19 |
2013-09-26 |
Alkermes Pharma Ireland Limited |
Pharmaaceutical compositions comprising fatty acid esters
|
JP6333802B2
(ja)
*
|
2012-03-19 |
2018-05-30 |
アルカームス ファーマ アイルランド リミテッド |
ベンジルアルコールを含む医薬組成物
|
NZ730571A
(en)
|
2012-09-19 |
2018-12-21 |
Alkermes Pharma Ireland Ltd |
Pharmaceutical compositions having improved storage stability
|
EP3119399A4
(en)
|
2014-03-20 |
2017-09-27 |
Alkermes Pharma Ireland Limited |
Aripiprazole formulations having increased injection speeds
|